A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
National Cancer Centre, Singapore
Memorial Sloan Kettering Cancer Center
University of Illinois at Chicago
Merck Sharp & Dohme LLC
National University Hospital, Singapore
Merck Sharp & Dohme LLC
National University Hospital, Singapore